Drug company Zydus Cadila announced on Thursday that Brexpiprazole tablets, used for the treatment of Schizophrenia, have received market approval from the US health regulator in the American market.
Tentual marketing approval for Brexpiprazol tablets of 0.25, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg was granted to the Company by the United States Food and Drug Administration (USFDA), the medicine company said in a statement.
Brexpiprazole is an atypical antipsychotic for the treatment of major depressive disorders (MDD) and schizophrenia, and is indicated as an adjunctive therapy with antidepressants.
Zydus Cadila noted that it would manufacture the drug at its manufacturing facility at the SEZ, Ahmedabad.
The Ahmedabad-based group now has 321 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.
Recent Posts
One Sleepless Night Can Weaken Your Immunity and Trigger Inflammation
Sleep is often regarded as a luxury in today’s fast-paced world, but scientific research continuously…
Thick Heart Syndrome: A Silent Threat to Millions in India
Heart disease remains one of the leading causes of death worldwide, and in India, cardiovascular…
Delhi Sees Surge in H1N1 and Influenza B Cases
Delhi is witnessing a sharp rise in flu cases, particularly Influenza B and H1N1 (commonly…
Woman Dies During MRI Scan Due to Medical Negligence
In early February 2025, a tragic incident occurred in Eluru, Andhra Pradesh, where a 61-year-old…
Holi and Eye Safety: Protect Your Vision During Festivities
Holi, the festival of colors, is one of the most vibrant and joyous celebrations in…
FDA Recalls Popular Skincare Products Over Cancer-Causing Chemical
In a major development, the U.S. Food and Drug Administration (FDA) has issued recalls for…